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Summary
Clinical characteristics
Snyder-Robinson syndrome (SRS) is an X-linked intellectual disability syndrome characterized by asthenic 
build, facial dysmorphism with a prominent lower lip, kyphoscoliosis, osteoporosis, speech abnormalities, and 
seizures. Developmental delay usually presents as failure to meet early developmental milestones and then 
evolves to moderate to profound intellectual disability (which appears to remain stable over time) and variable 
motor disability. Asthenic habitus and low muscle mass usually develop during the first year, even in males who 
are ambulatory. During the first decade, males with SRS develop osteoporosis, resulting in fractures in the 
absence of trauma.
Diagnosis/testing
The diagnosis of SRS is established by identification of a hemizygous loss-of-function SMS pathogenic variant on 
molecular genetic testing.
Management
Treatment of manifestations: Speech, physical, and/or occupational therapy may be helpful. Standard surgical 
treatment by craniofacial team for those with cleft palate. Calcium supplementation has slightly improved bone 
mineral density in a few individuals. Standard management of kyphoscoliosis by orthopedics. Seizures have 
shown varying responses to anti-seizure medications; Carbamazepine, phenobarbital, clobazam, levetiracetam, 
and valproic acid have been used successfully in some individuals.
Surveillance: Monitor developmental progress and educational needs. Clinical examination and DEXA scans to 
evaluate for progression of osteoporosis and investigate for factures if medically indicated. While receiving 
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calcium supplementation, individuals should be evaluated regularly for ectopic calcification by endocrinology. 
Clinical examinations for kyphoscoliosis at each visit. Monitor those with seizures as clinically indicated.
Genetic counseling
SRS is inherited in an X-linked manner. If the mother of the proband has a pathogenic variant, the chance of 
transmitting it in each pregnancy is 50%: Males who inherit the pathogenic variant will be affected; females who 
inherit the pathogenic variant will be carriers (to date, features of SRS have not been observed in heterozygous 
females). Affected males are not known to reproduce. Once an SMS pathogenic variant is identified in an 
affected family member, carrier testing for at-risk relatives, prenatal testing for pregnancies at increased risk, and 
preimplantation genetic testing are possible.
Diagnosis
Formal diagnostic criteria have not been established for Snyder-Robinson syndrome (SRS).
Suggestive Findings
Snyder-Robinson syndrome should be suspected in males with the following findings [Arena et al 1996, Cason 
et al 2003, de Alencastro et al 2008, Becerra-Solano et al 2009, Schwartz et al 2011, Peron et al 2013, Zhang et al 
2013, Albert et al 2015, Abela et al 2016]:
• Intellectual disability (100% [20/20]); classified as moderate to severe generalized psychomotor delay that 
begins in infancy. IQ ranges from unmeasurable to 60.
• Hypotonia (100% [20/20]); secondary to poor muscular development
• Asthenic body build and diminished body bulk (95% [19/20]). Many individuals also have measurably 
long fingers and toes.
• Bone abnormalities including osteoporosis (100% [14/14]), fractures and kyphoscoliosis (84%; 16/19 
individuals had both fractures and kyphoscoliosis), and joint contractures (15% [3/14])
• Facial dysmorphism including asymmetric face (64% [13/20]) and prominent lower lip (79% [16/20])
• Ambulation abnormalities ranging from unsteady gait to inability to walk (71% [14/19])
• Speech abnormalities including nasal, dysarthric, coarse, or absent speech (100% [19/19])
• Abnormal palate morphology including high, narrow, or cleft palate (83% [15/17])
• Mild short stature (73% [14/19]). Growth rates are normal but the length or height is at least 1 SD below 
the mean. Height in four of seven (on whom data are available) was less than 2 SD below the mean.
• Seizures (67%). Usually present by early childhood. Severity and frequency vary and success of treatment 
varies.
• Genital abnormalities (15% [3/20]) including low testicular volume, hypospadias, and undescended 
testes
• Renal complications (15% [3/20]). Nephrocalcinosis (unrelated to calcium administration) and renal 
cysts have been reported in three individuals with SRS.
Establishing the Diagnosis
Male proband. The diagnosis of Snyder-Robinson syndrome is established in a male proband with EITHER of 
the following:
• Spermine synthase (SMS) enzyme analysis. Decreased or absent SMS enzyme activity in fresh white cells 
or cultured lymphoblasts
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Note: Increased spermidine to spermine ratio in fresh white cells or cultured lymphoblasts is 
pathognomonic of SRS. (Absolute levels of spermidine or spermine do not differ significantly between 
affected individuals and controls.)
• Molecular genetic testing. Identification of a hemizygous loss-of-function pathogenic variant in SMS (see 
Table 1).
Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing 
and multigene panel) and comprehensive genomic testing (exome sequencing, genome sequencing, exome 
array or high-density microarray) depending on the phenotype.
Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic 
testing does not. Because the phenotype of Snyder-Robinson syndrome is broad, individuals with the distinctive 
findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), 
whereas those with a phenotype indistinguishable from many other inherited disorders with intellectual 
disability are more likely to be diagnosed using genomic testing (see Option 2).
Option 1
When the phenotypic findings suggest the diagnosis of Snyder-Robinson syndrome, molecular genetic testing 
approaches can include single-gene testing or use of a multigene panel:
• Single-gene testing. Sequence analysis of SMS detects small intragenic deletions/insertions and missense, 
nonsense, and splice site variants. If no pathogenic variant is found, performing gene-targeted deletion/
duplication analysis to detect intragenic deletions or duplications should be done if possible. Note: Lack of 
amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion 
on the X chromosome in affected males; confirmation requires additional testing by gene-targeted 
deletion/duplication analysis.
• An intellectual disability multigene panel that includes SMS and other genes of interest (see Differential 
Diagnosis) may be considered to identify the genetic cause of the condition at the most reasonable cost 
while limiting identification of variants of uncertain significance and pathogenic variants in genes that do 
not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic 
sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some 
multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In 
some laboratories, panel options may include a custom laboratory-designed panel and/or custom 
phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a 
panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based 
tests.
For an introduction to multigene click here. More detailed information for clinicians ordering genetic tests 
can be found here.
Option 2
When the phenotype is indistinguishable from many other inherited disorders characterized by intellectual 
disability, comprehensive genomic testing (which does not require the clinician to determine which gene[s] are 
likely involved) is the best option. Exome sequencing is most commonly used; genome sequencing, however, is 
slowly becoming the preferred approach.
If exome sequencing is not diagnostic, exome array (when clinically available) or high-density microarray may 
be considered to detect (multi)exon deletions or duplications that cannot be detected by sequence analysis.
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For an introduction to comprehensive genomic testing click here. More detailed information for clinicians 
ordering genomic testing can be found here.
Table 1. Molecular Genetic Testing Used in Snyder-Robinson Syndrome
Gene 1 Method Proportion of Probands with a Pathogenic Variant 2 Detectable by Method
SMS
Sequence analysis 3, 4 37/37 5
Gene-targeted deletion/duplication 
analysis 6
No pathogenic deletion/duplication has been 
reported in an affected male 7
1. See Table A. Genes and Databases for chromosome locus and protein.
2. See Molecular Genetics for information on allelic variants detected in this gene.
3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. 
Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon 
or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
4. Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X 
chromosome in affected males; confirmation requires additional testing by gene-targeted deletion/duplication analysis.
5. Peron et al [2013]; Zhang et al [2013]; Albert et al [2015]; Abela et al [2016]; Larcher et al [2020]; Schwartz et al, unpublished data.
6. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative 
PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect 
single-exon deletions or duplications.
7. Among more than 11,300 individuals studied, 14 deletions and duplications have been reported to span SMS (see Genetically Related 
Disorders). Two other variants of unknown significance are reported in the database of genomic variants: an intronic deletion observed 
in 36 unaffected male and female controls [Mills et al 2006] and an exon 7 deletion observed in an unaffected Korean male [Kim et al 
2009].
Clinical Characteristics
Clinical Description
Snyder-Robinson syndrome (SRS) is an X-linked intellectual disability syndrome with a specific clinical 
phenotype consisting of asthenic build, facial dysmorphism with a prominent lower lip, kyphoscoliosis, 
osteoporosis, and speech abnormalities.
To date, 20 individuals have been identified with a pathogenic variant in SMS [Peron et al 2013, Zhang et al 
2013, Albert et al 2015, Abela et al 2016, Larcher et al 2020]. The following description of the phenotypic features 
associated with this condition is based on these reports.
Table 2. Features of Snyder-Robinson Syndrome
Feature Proportion of Persons w/Feature Comment
Intellectual
disability 22/22 Moderate to severe
Hypotonia 22/22 Usually presents at birth & is persistent
Speech
abnormalities 19/21 Nasal, dysarthric, coarse, or absent
Ambulation
abnormalities 15/19 Ranges from unsteady gait to inability to walk
Asthenic
body build 19/20 Low muscle mass persistent
Short stature 14/19 1-2 SD below mean
Craniofacial
features 18/20 Incl asymmetric face, prominent lower lip, & high, narrow, or cleft palate
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Table 2. continued from previous page.
Feature Proportion of Persons w/Feature Comment
Early-onset
osteoporosis 16/16 Fractures
Seizures 15/22
Long hands 14/15
Long great toes 10/14
Onset. Developmental delay and facial dysmorphism manifest within the first year of life.
Developmental delay. Hypotonia is usually present in the neonatal period which can persist into early 
childhood. Developmental delay usually presents as failure to meet milestones and then evolves to moderate to 
profound intellectual disability. The majority of males with SRS (22 published, 13 unpublished) do not appear to 
have progressive cognitive decline; rather, they remain cognitively stable throughout their lifetime. Those who 
develop speech (10/14) develop it late, some as late as age five years. Most individuals with SRS are able to follow 
simple commands. For two individuals who had no speech, it is unclear if a contributing factor was the absence 
of social contact [de Alencastro et al 2008]. Delay in motor development, observed in the majority of individuals 
with SRS, usually presents with delays in normal movements that occur in early childhood and do not resolve.
Progression. All reported males with SRS have maintained previously acquired skills; however, two recently 
identified unreported males have had progressive neurologic decline and loss of previously obtained skills. The 
measured IQ and cognitive functioning were highest in the original family, possibly due to the presence of 
residual SMS enzyme activity [Snyder & Robinson 1969, Cason et al 2003].
Asthenic habitus and low muscle mass usually develop during the first year. Although decreased strength is not 
described in males with SRS, most have progressive loss of muscle mass. Loss of muscle mass occurs even in 
males who are ambulatory, suggesting that the loss is probably the result of an underlying defect, not lack of use.
Mild short stature (73%). Growth rates are normal but the length or height is at least 1 SD below the mean. 
However, height on the 13 males for which data was available was variable, ranging from the 95th percentile to 3 
SD below the mean.
Craniofacial features include asymmetric face (64% [13/20]), prominent lower lip (79% [16/20]), and high, 
narrow, or cleft palate (83% [15/17]). Head circumference is often in the upper centiles.
Osteoporosis. During the first decade of life, males with SRS develop osteoporosis. Most experience fractures in 
the absence of trauma or after minor trauma within the first decade, at which point the osteoporosis is 
discovered; the long bones are most severely affected. Among males reported, the osteoporosis and fracture 
activity do not progressively worsen with age but remain at the severity found at the time of diagnosis. Bone 
density measurements were documented in two individuals [Albert et al 2015]. The mechanism of decreased 
bone mineral density is not well understood
Other musculoskeletal features. Kyphoscoliosis (13/16) can appear within the first decade of life. This 
observation is rather rare in other X-linked conditions. Limb contractures are rare, having only been noted in 
four males. Abnormal pectus was noted in nine males.
Seizures (67%). Usually present by early childhood. Severity and frequency vary. In some affected individuals, 
seizures may be drug-resistant [Authors’ personal observation].
Brain MRI findings. In individuals for which brain imaging was done, ventricular dilation was noted in two of 
11 individuals, a thin corpus callosum was noted in three of ten individuals. Abnormal calcification (which has 
been noted in a few individuals) occurs in the absence of calcium supplementation.
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Genital abnormalities reported in 15% of males included low testicular volume, hypospadias, and undescended 
testes.
Renal complications have occurred in 15% of males including nephrocalcinosis (unrelated to calcium 
administration) and renal cysts reported in three individuals with SRS.
Skewed X-chromosome inactivation has been observed in heterozygous females in at least three families with 
SRS [Cason et al 2003; de Alencastro et al 2008; Author, personal communication]. It is unclear if skewed X-
chromosome inactivation is a protective mechanism. In at least one of the families, presence of the SMS 
pathogenic variant in a heterozygous female is not associated with skewing of X-chromosome inactivation 
[Cason et al 2003].
Genotype-Phenotype Correlations
No clear genotype-phenotype correlations have been established for Snyder-Robinson syndrome. Even within a 
family, the phenotype varies; for example, in one family IQ values ranged from 46 to 77.
Based on the limited data available, the c.166G>A (p.Gly56Ser), c.388C>T (p.Arg130Cys), and c.443A>G 
(p.Gln148Arg) pathogenic variants have been associated with more severe manifestations [de Alencastro et al 
2008, Albert et al 2015, Abela et al 2016].
A male infant with an SMS truncating variant, the first one observed, died a short time after birth [Larcher et al 
2020]. The clinical presentation was quite severe, with multiple organ systems involved.
Penetrance
All individuals with SRS have deficient spermine synthase enzyme activity. However, as its prevalence in the 
general population has not been determined, penetrance of deficient spermine synthase activity as SRS cannot 
be stated.
Sequence variants of SMS have been reported for one seemingly unaffected male [Kim et al 2009]. Spermine 
synthase activity was not measured, and thus the functional consequences of this variant are unclear.
Additionally, five other nonsynonymous SMS variants were identified in large sequencing cohorts; phenotype, 
sex, and enzyme function are unavailable for these individuals.
Nomenclature
When Snyder and Robinson first described this syndrome, they labeled it "recessive sex-linked mental 
retardation in the absence of other recognizable abnormalities" [Snyder & Robinson 1969]. It is now considered 
an X-linked intellectual disability syndrome with a specific clinical phenotype consisting of asthenic build, facial 
dysmorphism with a prominent lower lip, kyphoscoliosis, osteoporosis, seizures, and speech abnormalities (see 
Clinical Description).
Prevalence
The prevalence of SRS is unknown. Of the twenty individuals evaluated and reported in the current literature, 13 
were identified in the Americas: Mexico, Brazil, and the United States, and seven were identified in Western 
European countries, indicating that the disorder probably exists in most populations.
Genetically Related (Allelic) Disorders
No phenotypes other than those discussed in this GeneReview are known to be associated with germline 
pathogenic variants in SMS.
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Contiguous gene deletions including SMS. Among more than 11,300 individuals studied, 14 deletions and 
duplications have been reported to span SMS. Of the copy number variations (CNVs) spanning SMS, only one 
(which was detected in 2 women) caused clinical pathology: dysmorphic features, intellectual disability, and 
ocular abnormalities including oculomotor apraxia, heterochromia of the iris, and vision problems. 
Confounding attribution of these features to hemizygosity for SMS: the CNV deleting SMS also deleted 106 
other genes including 35 associated with other disorders; moreover, these women had another deletion spanning 
SHOX, which is associated with Leri-Weill dyschondrosteosis [Firth et al 2009].
Differential Diagnosis
X-linked intellectual disability syndromes with osteoporosis. The observation that 30% more males than 
females have intellectual disability (ID) suggests that pathogenic variants of genes on the X chromosome are 
among the most frequent causes of ID among males [Stevenson et al 2012]. X-linked intellectual disability (XID) 
should be considered in males who are simplex cases (i.e., a single occurrence of ID in a family) as well as in 
males with a family history of intellectual disability consistent with X-linked inheritance. Consideration of XID 
as a cause of ID in simplex cases is relevant since approximately 33% of pathogenic variants causing the more 
severe forms of XID arise de novo.
Distinguishing between various forms of syndromic ID by clinical findings alone is often difficult because of 
overlapping clinical features, and diagnosis frequently requires identification of the molecular cause. 
Nonetheless, Snyder-Robinson syndrome (SRS) can be distinguished from many forms of syndromic XID by the 
combination of hypotonia, facial dysmorphism, asthenic body build, and both osteoporosis and kyphoscoliosis. 
While kyphoscoliosis is visible, osteoporosis is not, although the presence of fractures is suggestive of it. Because 
osteoporosis is rare in XID, it can be utilized as a distinguishing feature and should certainly be considered in a 
male with fractures.
XID intellectual disability syndromes with overlapping findings of SRS and osteoporosis are summarized in 
Table 3.
Table 3. X-linked Intellectual Disability Syndromes with Overlapping Findings of Snyder-Robinson Syndrome and Osteoporosis
Gene(s) Differential Diagnosis Disorder
Clinical Features of Differential Diagnosis Disorder
Overlapping w/SRS Distinguishing from SRS
GK Glycerol kinase deficiency (OMIM 307030)
• DD
• Growth restriction
• Muscle weakness
• Osteoporosis
Adrenal insufficiency
GRIA3 GRIA3-related ID (OMIM 300699)
• ID
• Asthenic habitus
• Seizures
Aggressive behavior
MAOA
MAOB
NDP
Xp11.3 duplication 1
• Moderate-to-severe ID
• Osteoporosis
• Scoliosis
• Seizures
• Speech abnormalities
• Excessively friendly demeanor
• Normal facial features
• Normal stature
SLC16A2
MCT8-specific thyroid hormone cell-membrane 
transporter deficiency (Allan-Herndon-Dudley 
syndrome)
• ID
• Hypotonia
• ↓ muscle mass
• Unsteady gait / ataxia
Different facial features
DD = developmental delay, ID = intellectual disability, SRS = Snyder-Robinson syndrome
1. Klitten et al [2011]
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Other syndromes with osteoporosis to be considered in the differential diagnosis of SRS include the following:
• Cerebral palsy (CP). CP is a heterogeneous group of disorders arising from multiple genetic and 
environmental etiologies. In some individuals the phenotype overlaps that of SRS. Shared features can 
include seizures, osteoporosis, scoliosis, and developmental delay.
• Prader-Willi syndrome(PWS). Neonatal hypotonia, developmental delay, osteoporosis, and scoliosis are 
also features of PWS. Unlike individuals with SRS, those with PWS have metabolic syndrome, obesity, and 
severe behavior problems. PWS is caused by abnormal parent-specific imprinting within the Prader-Willi 
critical region (PWCR) on chromosome 15. The risk to the sibs of an affected child of having PWS 
depends on the genetic mechanism that resulted in the absence of expression of the paternally contributed 
15q11.2-q13 region.
• Urban syndrome, described in two teenage males, in one family, is characterized by intellectual disability, 
osteoporosis, and short stature [Urban et al 1979]. Unlike SRS, affected males were obese with normal 
muscle tone. The molecular basis of Urban syndrome is unknown.
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with Snyder-Robinson syndrome (SRS), 
the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are 
recommended:
Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Snyder-Robinson Syndrome
System/Concern Evaluation Comment
Development Developmental assessment
• To incl motor, adaptive, cognitive, & speech/language 
evaluation
• Evaluation for early intervention / special education
Constitutional Weight, length/height, & head circumference Assess for evidence of short stature, macrocephaly.
Cleft palate Clinical evaluation incl feeding assessment
Musculoskeletal
Bone density assessment by DEXA scan To determine degree of osteoporosis & need for calcium supplements or bisphosphonates 1
Clinical evaluation for kyphoscoliosis Consider radiographic scoliosis survey based on clinical suspicion & referral for orthopedic surgery as appropriate.
Neurologic Neurologic evaluation
• Assessment for hypotonia
• To incl brain MRI to assess abnormal calcification &/or brain 
abnormalities
• Consider EEG if seizures are a concern.
Genitourinary Renal ultrasound To assess for renal abnormalities (rare)
Miscellaneous/
Other
Consultation w/clinical geneticist &/or 
genetic counselor To incl genetic counseling
DEXA = dual-energy x-ray absorptiometry
1. Bisphosphonates have been used for osteoporosis in general; their efficacy in Snyder-Robinson syndrome has not been 
demonstrated, and initial evidence of efficacy is controversial.
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Treatment of Manifestations
Table 5. Treatment of Manifestations in Individuals with Snyder-Robinson Syndrome
Manifestation/
Concern Treatment Considerations/Other
DD/ID Speech therapy, PT, &/or OT
Some individuals have performed appropriately in special education 
programs, learned to follow commands, & held simple jobs [Arena et al 
1996]; others showed no improvement of psychomotor skills w/special 
education [Becerra-Solano et al 2009].
Cleft palate Standard surgical treatment per craniofacial team
Osteoporosis Calcium supplementation
• Calcium supplementation has slightly improved bone mineral 
density in a few individuals [Becerra-Solano et al 2009]. Calcium 
supplementation should be started once ↓ bone mineral density is 
noted.
• The use of bisphosphonates is controversial & no studies currently 
demonstrate their effectiveness [Albert et al 2015].
Kyphoscoliosis Standard management as recommended by orthopedist
Epilepsy Standardized treatment w/AEDs by experienced neurologist 1
• Carbamazepine, phenobarbital, clobazam, levetiracetam & 
valproic acid have successfully controlled seizures in some 
individuals.
• Avoid medications known to affect bone (e.g., some AEDs) as they 
can potentially worsen osteoporosis & ↑ risk of spontaneous 
fractures.
AEDs = antiepileptic drugs; DD/ID = developmental delay / intellectual disability; OT = occupational therapy; PT = physical therapy
1. Education of parents regarding common seizure presentations is appropriate. For information on non-medical interventions and 
coping strategies for parents or caregivers of children diagnosed with epilepsy, see Epilepsy & My Child Toolkit.
Surveillance
Table 6. Recommended Surveillance for Individuals with Snyder-Robinson Syndrome
System/Concern Evaluation Frequency
DD/ID Monitor developmental progress & educational needs At each visit
Osteoporosis
• Clinical examination & DEXA scans to monitor progression of 
osteoporosis
• Radiographs to investigate for factures
When medically indicated
Ectopic calcification Referral to endocrinologist to manage calcium supplementation due to risk of ectopic calcification.
Kyphoscoliosis • Monitor for scoliosis.• Orthopedic evaluation as indicated Monitor clinically at each visit.
Neurologic Monitor those w/seizures as clinically indicated. When medically indicated
DD/ID = developmental delay / intellectual disability; DEXA = dual-energy x-ray absorptiometry
Evaluation of Relatives at Risk
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
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Therapies Under Investigation
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on 
clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this 
disorder.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, 
and implications of genetic disorders to help them make informed medical and personal decisions. The following 
section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for 
family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may 
face or to substitute for consultation with a genetics professional. —ED.
Mode of Inheritance
Snyder-Robinson syndrome (SRS) is inherited in an X-linked manner.
Risk to Family Members
Parents of a male proband
• The father of an affected male will not have the disorder nor will he be hemizygous for the SMS 
pathogenic variant; therefore, he does not require further evaluation/testing.
• In a family with more than one affected individual, the mother of an affected male is an obligate 
heterozygote (carrier). Note: If a woman has more than one affected child and no other affected relatives 
and if the SMS pathogenic variant cannot be detected in her leukocyte DNA, she most likely has germline 
mosaicism. There are no data regarding frequency or possibility of germline mosaicism in SRS.
• If a male is the only affected family member (i.e., a simplex case), the mother may be a heterozygote 
(carrier) or the affected male may have a de novoSMS pathogenic variant, in which case the mother is not 
a carrier. Of the 20 published cases reported to date, two individuals were shown to have SRS as the result 
of a de novo pathogenic variant.
Sibs of a male proband. The risk to sibs depends on the genetic status of the mother:
• If the mother of the proband has an SMS pathogenic variant, the chance of transmitting it in each 
pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the 
pathogenic variant will be heterozygotes (carriers). In the families reported to date, features of SRS have 
not been observed in heterozygous females.
• If the proband represents a simplex case (i.e., a single occurrence in a family) and if the SMS pathogenic 
variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is greater than that of the 
general population because of the possibility of maternal germline mosaicism.
Offspring of a male proband. Affected males are not known to reproduce.
Other family members. The proband's maternal aunts may be at risk of being heterozygotes (carriers) for the 
pathogenic variant and the aunts' offspring, depending on their gender, may be at risk of being carriers for the 
pathogenic variant or of being affected.
Note: Molecular genetic testing may be able to identify the family member in whom a de novo pathogenic 
variant arose, information that could help determine genetic risk status of the extended family.
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Heterozygote (Carrier) Detection
Molecular genetic testing of at-risk female relatives to determine their genetic status requires prior identification 
of the pathogenic variant in the family.
Note: Females are heterozygotes for this X-linked disorder; hypothetically, they could develop clinical findings 
related to the disorder secondary to partial loss of SMS function or skewing of X-chromosome inactivation. To 
date, no identified heterozygotes have had signs or symptoms attributable to their SMS pathogenic variant.
Related Genetic Counseling Issues
Family planning
• The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the 
availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and 
reproductive options) to young adults who are carriers or are at risk of being carriers.
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because 
it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in 
the future, consideration should be given to banking DNA of affected individuals.
Prenatal Testing and Preimplantation Genetic Testing
Once the SMS pathogenic variant has been identified in an affected family member, prenatal testing for a 
pregnancy at increased risk and preimplantation genetic testing are possible.
Differences in perspective may exist among medical professionals and within families regarding the use of 
prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather 
than early diagnosis. While most centers would consider use of prenatal testing to be a personal decision, 
discussion of these issues may be helpful.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries 
for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the 
information provided by other organizations. For information on selection criteria, click here.
• Snyder-Robinson Foundation
McLean VA
Phone: 703-533-9844
Email: info@snyder-robinson.org
www.snyder-robinson.org
• Medline Plus
Intellectual Disability
• National Library of Medicine Genetics Home Reference
Snyder-Robinson syndrome
• EuroMRX Consortium Registry
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Radboud University Nijmegen Medical Centre, Department of Human Genetics
PO Box 9101
Nijmegen 6500 HB
Netherlands
Phone: +31 24 3614017
Fax: +31 24 3668752
Email: a.debrouwer@antrg.umcn.nl
www.euromrx.com
• Human Disease Genes Website Series - Registry
This website was created to share and collect information about clinic, management and research projects to 
gather more knowledge and provide better treatment of patients with mutations in the SMS gene.
SMS
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables 
may contain more recent information. —ED.
Table A. Snyder-Robinson Syndrome: Genes and Databases
Gene Chromosome Locus Protein Locus-Specific 
Databases
HGMD ClinVar
SMS Xp22.11 Spermine synthase SMS @ LOVD SMS SMS
Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. 
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.
Table B. OMIM Entries for Snyder-Robinson Syndrome (View All in OMIM)
300105 SPERMINE SYNTHASE; SMS
309583 MENTAL RETARDATION, X-LINKED, SYNDROMIC, SNYDER-ROBINSON TYPE; MRXSSR
Molecular Pathogenesis
Polyamines are small organic molecules containing at least two amino groups, which play a wide range of 
regulatory functions in the cell thereby ensuring normal cell growth, differentiation, and survival [Murray-
Stewart et al 2018]. SMS encodes spermine synthase (SMS), which catalyzes the production of spermine, a 
polyamine, from spermidine and decarboxylated S-adenosylmethionine (dcSAM). Pathogenic variants in SMS 
lead to an almost total loss of enzymatic activity which in turn leads to a lack of spermine and an increase in 
spermidine. Therefore, Snyder-Robinson syndrome is a polyamine deficiency syndrome [Cason et al 2003].
Mechanism of disease causation. Loss of function
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Table 7. Notable SMS Pathogenic Variants
Reference Sequences DNA Nucleotide Change Predicted Protein Change Comment [Reference]
NM_004595.4
NP_004586.2
c.166G>A p.Gly56Ser
Assoc w/severe manifestations [de Alencastro et al 2008, 
Lemke et al 2012, Albert et al 2015, Abela et al 2016, 
Larcher et al 2020]
c.174T>A p.Phe58Leu
c.388C>T p.Arg130Cys
c.443A>G p.Gln148Arg
c.908_911del p.Met303LysfsTer3
Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of 
variants.
GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen.hgvs.org). See Quick 
Reference for an explanation of nomenclature.
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